More Bowel Disease Patients Are Switching Therapies Than a Year Ago, Report Says

More Bowel Disease Patients Are Switching Therapies Than a Year Ago, Report Says
More inflammatory bowel disease patients are switching biologic therapies than in 2016, according to a report by Spherix Global Insights RealWorld Dynamix. The appearance of Janssen’s Stelara (ustekinumab) — approved for Crohn’s disease last year — dramatically impacted the switching patterns, according to the findings. More than 1,000 medical records of IBD patients who switched

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

Leave a Comment

Your email address will not be published. Required fields are marked *